Clinical trials: Non-small Cell Lung Cancer Metastatic
Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous…
- Trial name
- NCT06692738
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 333 sites in United States, Argentina and 24 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
NSCLC Stage IV
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1)…
- Trial name
- NCT06745908
- Testing
- N-803, Tislelizumab, Docetaxel
- Where
- 49 sites in United States, Canada and 1 more
- Volunteers
- 507 people
- Sponsor
- ImmunityBio, Inc.
Lung Cancer
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung cance.
- Trial name
- NCT04993391
- Testing
- JS111(AP-L1898 Capsules)
- Where
- 37 sites in China
- Volunteers
- 32 people
- Sponsor
- Suzhou Junjing BioSciences Co., Ltd.
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Advanced or Metastatic NSCLC
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.
- Trial name
- NCT05435248
- Testing
- HS-10375
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
This is a Phase 1B study designed to assess the safety and tolerability of LYC-55716 given in combination with pembrolizumab to subjects with metastatic NSCLC, and to assess the combination for biologic and clinical activity in…
- Trial name
- NCT03396497
- Testing
- LYC-55716, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Lycera Corp.
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable…
- Trial name
- B-FAST (NCT03178552)
- Testing
- Alectinib, Atezolizumab, Pemetrexed
- Where
- 161 sites in United States, Argentina and 25 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma
- Trial name
- NCT07903415
- Testing
- PF-08098488
- Where
- 4 sites in United States
- Volunteers
- 280 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)
This study including two parts，one part is a randomized clinical trial design，another part is a registration study.
- Trial name
- NCT03198117
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Solid Tumor, Adult, Breast Cancer
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer
- Trial name
- NCT03149549
- Testing
- CX-2009
- Where
- 26 sites in United States, Netherlands and 2 more
- Volunteers
- 99 people
- Sponsor
- CytomX Therapeutics
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer
Study to Evaluate CCS1477 in Advanced Tumours
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT03568656
- Testing
- CCS1477, Abiraterone acetate, Enzalutamide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 219 people
- Sponsor
- CellCentric Ltd.
Lung Cancer, Non-small Cell Lung Cancer
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy…
- Trial name
- NCT03390686
- Testing
- Bevacizumab, HD204, Carboplatin
- Where
- 18 sites in Belarus, Bulgaria and 15 more
- Volunteers
- 650 people
- Sponsor
- Prestige Biopharma Limited
Non-small Cell Lung Cancer
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
TLK199.2102 was a multicenter Phase 2 randomized study to determine the effect of Telintra treatment on chemotherapy induced neutropenia (CIN) in patients with non small cell lung cancer receiving first-line therapy with…
- Trial name
- NCT00701870
- Testing
- ezatiostat hydrochloride (Telintra®)
- Where
- 24 sites in United States
- Volunteers
- 1 people
- Sponsor
- Telik
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Non-small Cell Lung Cancer, Brain Metastases
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
The purpose of this study is to evaluate the safety and tolerability of Icotinib at different dose levels in combination with whole brain radiotherapy for NSCLC patients with brain metastases and EGFR mutation.
- Trial name
- NCT01516983
- Testing
- icotinib, Whole brain radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants…
- Trial name
- NCT06212752
- Testing
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin
- Where
- 18 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Non Small Cell Lung Cancer
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced…
- Trial name
- NCT04032847
- Testing
- ATL001, Pembrolizumab
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 27 people
- Sponsor
- Achilles Therapeutics UK Limited
EGFR T790M Mutation Positive NSCLC
AZD9291 US Expanded Access Program
To provide access to AZD9291 for adult patients with advanced/metastatic, epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
- Trial name
- NCT02451852
- Testing
- AZD9291
- Where
- 32 sites in United States
- Sponsor
- AstraZeneca
Lung Cancer, Non-Small Cell
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain.
- Trial name
- NCT00390806
- Testing
- HYCAMTIN, oral capsules, Radiation
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor, Esophageal Cancer
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with…
- Conditions
- Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers
- Trial name
- NCT06682806
- Testing
- PRT3789, pembrolizumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Prelude Therapeutics Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.